CRYSTALLINE FORMS OF (3-AMINO-OXETAN-3-YLMETHYL)-[2-(5,5-DIOXO-5,6,7,9-TETRAHYDRO-5LAMBDA*6*-THIA-8-AZA-BENZOCYCLOHEPTEN-8-YL)-6-METHYL-QUINAZOLIN-4-YL]-AMINE
The present invention relates to novel crystalline forms of compound (I),(3-Amino-oxetan-3-ylmethyl)-[2-(5,5-dioxo-5,6,7,9-tetrahydro-5lambda*6*-thia-8-aza-benzocyclohepten-8-yl)-6-methyl-quinazolin-4-yl]-amine and pharmaceutical compositions comprising the crystalline forms thereof disclosed herein, which may be used for the treatment or prophylaxis of a viral disease in a patient relating to respiratory syncytial virus (RSV) infection or a disease caused by RSV infection.